FREDRIC N ESHELMAN
CIK 1033409 · Executive Chairman · last filed 2022-10-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$185.79M
Companies
7
Total Filings
114
Lifetime Open-Market Net
$26.79M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Aravive, Inc. (ARAV) Delisted | Executive Chairman | 25,517,889 | $0.04 | $1.02M | $0 | 3 | 2022-10-26 |
| HYPERION DEFI, INC. (EYEN) Delisted | Director | 20,236 | $15.82 | $320.1K | $3.35M | 5 | 2021-11-22 |
| LQDA | 10%+ Owner | 2,776,783 | $66.91 | $185.79M | -$16.43M | 7 | 2021-01-27 |
| G1 Therapeutics, Inc. (GTHX) Delisted | Director | 3,689,151 | $7.15 | $26.38M | $9.43M | 6 | 2020-06-12 |
| MEDICINES CO /DE (MDCO) Delisted | Executive Chairman | 2,076,686 | — | — | $36.41M | 8 | 2018-06-04 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | Director | 2,715,188 | — | — | $35.19M | 28 | 2013-07-02 |
| PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted | Executive Chairman | 0 | — | — | -$41.16M | 50 | 2011-12-06 |
Recent Filings · Page 4 of 12
114 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-05-31 | MEDICINES CO /DE (MDCO) Delisted | Grant (A) | +3,426 | $0 | EDGAR |
| 2016-05-13 | MEDICINES CO /DE (MDCO) Delisted | Buy (P) | +300,000 | $10.10M | EDGAR |
| 2016-03-15 | — | Grant (A) | +1,096 | $0 | |
| 2015-11-25 | MEDICINES CO /DE (MDCO) Delisted | Buy (P) | — | $0 | EDGAR |
| 2015-09-01 | MEDICINES CO /DE (MDCO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-07-07 | — | Disp (D) | −2,848,017 | $0 | |
| 2013-07-02 | Furiex Pharmaceuticals, Inc. (FURX) Delisted | Grant (A) | +7,161 | $0 | EDGAR |
| 2012-06-22 | Furiex Pharmaceuticals, Inc. (FURX) Delisted | Exer (M) | +65,875 | $600.1K | EDGAR |
| 2012-06-15 | Furiex Pharmaceuticals, Inc. (FURX) Delisted | Buy (P) | +78,326 | $1.46M | EDGAR |
| 2012-06-04 | Furiex Pharmaceuticals, Inc. (FURX) Delisted | Buy (P) | +120,394 | $2.40M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.